Metronomic dosing enhances the anti-angiogenic effect of epothilone B

Journal of Surgical Research

Volumn 169, Issue 2, 2011, Pages 247-256

  Stalder, Mark W ^a   Anthony, Catherine T ^a   Woltering, Eugene A ^a,b  

^a LOUISIANA STATE UNIVERSITY   (United States)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

angiogenesis; cancer; epothilone B; human; metronomic

Indexed keywords

EPOTHILONE B;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; MAXIMUM TOLERATED DOSE; PRIORITY JOURNAL;

ANGIOGENESIS INHIBITORS; CARCINOID TUMOR; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; EPOTHILONES; GASTROINTESTINAL STROMAL TUMORS; HUMANS; INTESTINAL NEOPLASMS; LIVER NEOPLASMS; MALE; NEOVASCULARIZATION, PATHOLOGIC; TESTICULAR NEOPLASMS;

EID: 79960226709     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2009.12.001     Document Type: Article

References (32)

1. H.E. Skipper, F.M. Schabel Jr., and W.S. Wilcox Experimental evaluation of potential anticancer agents (XIII) on the criteria and kinetics associated with "curability" of experimental leukemia Cancer Chemother Rep 35 1964 1
2. A.A. Kamat, T.J. Kim, and C.N. Landen Jr. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer Cancer Res 67 2007 281
3. G. Bocci, K.C. Nicolaou, and R.S. Kerbel Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective anti-angiogenic window for various chemotherapeutic drugs Cancer Res 62 2002 6938
4. J. Wang, P. Lou, and R. Lesniewski Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly Anticancer Drugs 14 2003 13
5. G. Klement, S. Baruchel, and J. Rak Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity J Clin Invest 105 2000 R15
6. S. Man, G. Bocci, and G. Francia Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water Cancer Res 62 2002 2731
7. T. Browder, C.E. Butterfield, and B.M. Kraling Anti-angiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer Cancer Res 60 2000 1878
8. F. Bertolini, S. Paul, and P. Mancuso Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells Cancer Res 63 2003 4342
9. L. Bello, G. Carrabba, and C. Giussani Low-dose chemotherapy combined with an anti-angiogenic drug reduces human glioma growth in vivo Cancer Res 61 2001 7501
10. S.Z. Soffer, E. Kim, and J.T. Moore Novel use of an established agent: Topotecan is anti-angiogenic in experimental Wilms tumor J Pediatr Surg 36 2001 1781
11. G. Klement, P. Huang, and B. Mayer Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts Clin Cancer Res 8 2002 221
12. I.F. Hermans, T.W. Chong, and M.J. Palmowski Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model Cancer Res 63 2003 8408
13. S.D. Young, M. Whissell, and J.C. Noble Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofecoxib in patients with advanced solid tumors Clin Cancer Res 12 2006 3092
14. M. Colleoni, A. Rocca, and M.T. Sandri Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: Antitumor activity and correlation with vascular endothelial growth factor levels Ann Oncol 13 2002 73
15. L. Orlando, A. Cardillo, and A. Rocca Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer Anticancer Drugs 17 2006 961
16. R.J. Kowalski, P. Giannakakou, and E. Hamel Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol(R)) J Biol Chem 272 1997 2534
17. K. Kamath, and M.A. Jordan Suppression of microtubule dynamics by epothilone B is associated with mitotic arrest Cancer Res 63 2003 6026
18. S.H. Lee, S.M. Son, and D.J. Son Epothilones induce human colon cancer SW620 cell apoptosis via the tubulin polymerization independent activation of the nuclear factor-κB/IκB kinase signal pathway Mol Cancer Ther 6 2007 2786
19. D.M. Bollag, P.A. McQueney, and J. Zhu Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action Cancer Res 55 1995 2325
20. T.C. Chou, X.G. Zhang, and C.R. Harris Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel Proc Natl Acad Sci U S A 95 1998 15798
21. E.H. Rubin, J. Rothermel, and F. Tesfaye Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors J Clin Oncol 23 2005 9120
22. M.N. Bijman, G.P. van Nieuw Amerongen, and N. Laurens Microtubule-targeting agents inhibit angiogenesis at sub-toxic concentrations, a process associated with inhibition of Rac1 and Cdc42 activity and changes in the endothelial cytoskeleton Mol Cancer Ther 5 2006 2348
23. E.A. Woltering, J.M. Lewis, and P.J. Maxwell Development of a novel in vitro human tissue-based angiogenesis assay to evaluate the effect of anti-angiogenic drugs Ann Surg 237 2003 790
24. J.C. Watson, J.G. Redmann, and M.O. Meyers Breast cancer increases initiation of angiogenesis without accelerating neovessel growth rate Surgery 122 1997 508
25. S. Kesari, D. Schiff, and L. Doherty Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults Neuro Oncol 9 2007 354
26. L. Zhang, D. Yu, and D.J. Hicklin Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis Cancer Res 62 2002 2034
27. H. Hurwitz, L. Fehrenbacher, and W. Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335
28. G. Bocci, G. Francia, and S. Man Thrombospondin 1, a mediator of the anti-angiogenic effects of low-dose metronomic chemotherapy Proc Natl Acad Sci USA 100 2003 12917
29. P. Hahnfeldt, J. Folkman, and L. Hlatky Minimizing long-term tumor burden: The logic for metronomic chemotherapeutic dosing and its anti-angiogenic basis J Theor Biol 220 2003 545
30. P. Fumoleau, B. Coudert, and N. Isambert Novel tubulin-targeting agents: Anticancer activity and pharmacologic profile of epothilones and related analogues Ann Oncol 18 Suppl 5 2007 v9
31. J.M. Larkin, and S.B. Kaye Potential clinical applications of epothilones: A review of phase II studies Ann Oncol 18 Suppl 5 2007 v28
32. C. Sessa, A. Perotti, and A. Llado Phase I clinical study of the novel epothilone B analogue BMS-310705 given on a weekly schedule Ann Oncol 18 2007 1548